Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLS | O94925 | 5/20 | 0.54 |
| ▸ | KDM4A | O75164 | 1/20 | 0.48 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.48 |
| ▸ | BRD4 | O60885 | 3/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | ACACB | O00763 | 2/20 | 0.47 |
| ▸ | ACACA | Q13085 | 2/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.47 |
| ▸ | NAMPT | P43490 | 2/20 | 0.45 |
| ▸ | CA12 | O43570 | 1/20 | 0.45 |
| ▸ | CA1 | P00915 | 1/20 | 0.45 |
| ▸ | CA7 | P43166 | 1/20 | 0.45 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.45 |
| ▸ | HTR2C | P28335 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL31609012 | 0.99 | GLS (0.53) | GLSKDM4ALOXL2BRD4CYP1A2 | |
| SCHEMBL15656811 | 0.89 | GLS (0.53) | GLSKDM4ABRD4CREBBPNAMPT | |
| SCHEMBL27113184 | 0.89 | AOC3 (0.56) | GLSKDM4ABRD4CYP3A4CREBBP | |
| SCHEMBL27113191 | 0.88 | KDM4A (0.46) | GLSKDM4AACACBACACANAMPT | |
| SCHEMBL99337 | 0.88 | TPSAB1 (0.56) | KDM4ALOXL2CYP1A2CYP2C9CYP2D6 | |
| SCHEMBL13981921 | 0.87 | GLS (0.55) | GLSKDM4ABRD4CYP3A4CREBBP | |
| SCHEMBL16181822 | 0.87 | GLS (0.55) | GLSKDM4ABRD4CYP3A4CREBBP | |
| SCHEMBL30069429 | 0.87 | GLS (0.55) | GLSKDM4ABRD4CYP3A4CREBBP | |
| SCHEMBL1165088 | 0.87 | GLS (0.55) | GLSKDM4ABRD4CYP3A4CREBBP | |
| SCHEMBL8342682 | 0.87 | GLS (0.55) | GLSKDM4ABRD4CREBBPNAMPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 287 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-105030693-A | Lung-targeting gelatin microsphere agent containing cefquinome sulfate and preparation method of lung-targeting gelatin microsphere agents | UNIV QINGDAO AGRICULTURAL | 2015-11-11 | — | — | CN | claimed |
| US-20260028342-A1 | ENHANCING ANTIMETASTASIS ACTIVITY USING TARGETED PROTEIN DEGRADATION | UNIV NORTH CAROLINA CHAPEL HILL (US) | 2026-01-29 | — | — | US | disclosed |
| US-12479840-B2 | HMG-CoA reductase degradation inducing compound | UPPTHERA INC. (KR) | 2025-11-25 | — | — | US | disclosed |
| EP-4536638-A2 | INHIBITORS OF BACTERIAL TYPE III SECRETION SYSTEM | Microbiotix, Inc. (US) | 2025-04-16 | — | — | EP | disclosed |
| EP-4526303-A1 | N6-ADENOSINE-METHYLTRANSFERASE PROTACS AND METHODS OF USE THEREOF | University of Zurich (CH) | 2025-03-26 | — | — | EP | disclosed |
| WO-2025049326-A1 | TRICYCLIC HETEROAROMATIC INHIBITORS OF KLK5 | BIOCRYST PHARMACEUTICALS, INC. (US) | 2025-03-06 | — | — | WO | disclosed |
| US-20250074904-A1 | NSD2-TARGETED CHECMICAL DEGRADERTS AND COMPOSITIONS AND METHODS OF USE THEREOF | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL | 2025-03-06 | — | — | US | disclosed |
| CN-119487029-A | N6-adenosyl-methyltransferase PROTAC and methods of use thereof | 苏黎世大学 | 2025-02-18 | — | — | CN | disclosed |
| US-20240066135-A1 | DRUG CONJUGATES AND USES THEREOF | SUPERTRANS MEDICAL LTD (IL) | 2024-02-29 | — | — | US | disclosed |
| US-20240066135-A1 | DRUG CONJUGATES AND USES THEREOF | SUPERTRANS MEDICAL LTD (IL) | 2024-02-29 | — | — | US | disclosed |
| EP-0723438-A1 | SUBSTITUTED UREA AND ISOTHIOUREA DERIVATIVES AS NO SYNTHASE INHIBITORS | THE WELLCOME FOUNDATION LIMITED (GB) | 1996-07-31 | — | — | EP | disclosed |
| WO-1996019440-A1 | ACETAMIDINE DERIVATIVES AND THEIR USE AS INHIBITORS FOR THE NITRIC OXIDE SYNTHASE | THE WELLCOME FOUNDATION LIMITED (GB) | 1996-06-27 | — | — | WO | disclosed |
| WO-1995032945-A1 | COMPOSITIONS AND METHODS FOR TREATING MAST-CELL MEDIATED CONDITIONS | ARRIS PHARMACEUTICAL CORPORATION (US) | 1995-12-07 | — | — | WO | disclosed |
| EP-0674623-A1 | BICYCLIC FIBRINOGEN ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 1995-10-04 | — | — | EP | disclosed |
| EP-0672658-A1 | Antithrombotic agents | ELI LILLY AND COMPANY (US) | 1995-09-20 | — | — | EP | disclosed |
| WO-1995023609-A1 | ANTITHROMBOTIC AGENTS | ELI LILLY AND COMPANY (US) | 1995-09-08 | — | — | WO | disclosed |
| WO-1995009619-A2 | SUBSTITUTED UREA AND ISOTHIOUREA DERIVATIVES AS NO SYNTHASE INHIBITORS | THE WELLCOME FOUNDATION LIMITED (GB) | 1995-04-13 | — | — | WO | disclosed |
| CN-1094718-A | Bicyclic fibrinogen antagonists | SMITHKLINE BEECHAM CORP (US) | 1994-11-09 | — | — | CN | disclosed |
| WO-1994014776-A2 | BICYCLIC FIBRINOGEN ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 1994-07-07 | — | — | WO | disclosed |
| US-4624943-A | Aromatic basic-tailed vasopressin antagonists | SMITHKLINE BECKMAN CORPORATION (US) | 1986-11-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260028342-A1 | ENHANCING ANTIMETASTASIS ACTIVITY USING TARGETED PROTEIN DEGRADATION | EEF1A2, EEF1E1, EEF1D | GLS 2439/4885KDM4A 3690/4885LOXL2 2257/4885 |
| US-20250074904-A1 | NSD2-TARGETED CHECMICAL DEGRADERTS AND COMPOSITIONS AND METHODS OF USE THEREOF | NCOR2, NSD2, NCOR1 | GLS 4538/4885KDM4A 343/4885LOXL2 1638/4885 |
| US-12479840-B2 | HMG-CoA reductase degradation inducing compound | HMGCR, HMGB2, LDLR | GLS 1762/4885KDM4A 766/4885LOXL2 429/4885 |
| US-20240066135-A1 | DRUG CONJUGATES AND USES THEREOF | SLC7A1, ABCB11, SLC1A5 | GLS 230/4885KDM4A 4030/4885LOXL2 3259/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.